Scinai Immunotherapeutics (SCNI) H1 FY26 earnings call

Scinai Immunotherapeutics presented its H1 FY26 results in a corporate overview webinar, highlighting a significant transformation driven by the acquisition of Recipharm's Yavne operations. The company is now focused on executing its expanded two-platform strategy, converting customer activity into revenue, increasing CDMO utilization, and advancing its R&D pipeline with capital discipline. Management emphasized that while reported net income was positive due to an accounting gain, the underlying business generated an operating loss, necessitating a combination of operational execution and sel